Overall verdict
Neutral
4.3/10
1-year performance
+51.83%
Score breakdown
Up 51.8% over 1 year, 76% of the 52-week range.
Strongest: Growth 6.7/10. Weakest: Shareholder return 0.0/10.
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Andrew Toy
Founded
2014
Employees
724
Revenue / employee
2.7M USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.6.70%
- VANGUARD CAPITAL MANAGEMENT LLC3.44%
- GEODE CAPITAL MANAGEMENT, LLC2.07%
- STATE STREET CORP1.94%
- Nuveen, LLC1.20%
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.05%
- VANGUARD PORTFOLIO MANAGEMENT LLC0.85%
- NORTHERN TRUST CORP0.72%
- PNC Financial Services Group, Inc.0.68%
- Other institutions9.08%
- Rest of the register72.25%
226 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
5.59 USD
52-week low
1.58 USD
1-year performance
51.83%
Rising
Year-to-date performance
92.02%
Rising
Drawdown
-17.08%
Marked drawdown
Position in the 52-week range
76% of range
Range: 1.84 USD - 2.26 USD (comparables only)
The price implies growth of 11.43% per year; the company grows at 22.90%.
Gross margin 13.5%, the company loses 0.7% of its revenue, ROIC -5.1%, ROE -5.1%.
Net margin
-0.74%
Negative
Sector 1.68%|S&P 12.97%
Gross margin
13.52%
Low
Return on equity (ROE)
-5.10%
Negative
Sector 10.87%|S&P 16.52%
Return on invested capital (ROIC)
-5.10%
Negative
Free cash flow margin (FCF)
3.00%
Fair
Margin stability
15.1 pts
Very uneven
Revenue to net income
Growth
6.7/10Revenue up 55.6% over 1 year, 22.9% a year over 5.
Revenue (trailing 12 months)
2.5Md USD
Revenue growth (1y)
55.60%
Hyper-growth
Revenue growth (3y)
-44.81%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
55.56%
Sharply revised up
Valuation
5.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
57.9x
Very expensive
Sector 28.2x|S&P 23.0x
Forward P/E
82.1x
Very expensive
EV / EBITDA
—
N/A (loss)
Sector 15.4x|S&P 14.5x
PEG
0.17
Growth unpriced
Sector 0.59|S&P 0.86
Fair value (reverse DCF)
2.05 USD
Deeply overvalued
Market cap
2.4Md USD
net debt/EBITDA 3.5x.
Net debt / EBITDA
3.5x
Stretched
Gearing (net debt / equity)
-52.85%
Net cash
Cash
78.3M USD
Cash / market cap
3.23%
Tight
Net debt
-199M USD
Equity
376M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 4.51 USD
- MM204.47
- MM504.42
- MM2003.28
- RSI 1450.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.81%
200-day average slope, 3 months
+18.97%
50-day average slope, 1 month
-4.72%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.38 % per day
Volatility change
-11.91%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 0.06 (4) | 0.14 (1) | 2 954 (4) | 80 (3) | 31 (4) |
| 2027 | 0.10 (4) | 0.15 (1) | 3 525 (4) | 115 (3) | 68 (3) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 10, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.5 | 7.8 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | SAUD3 | 7.4 | 6.5 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | HQY | 6.9 | 6.2 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 4 | UNH | 6.9 | 5.9 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 5 | ELV | 6.5 | 5.4 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | CNC | 5.9 | 4.8 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.4 | 3.9 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 8 | MOH | 4.4 | 2.5 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % | ||
| 9 | CLOV | 4.3 | 3.3 | 2.4Md USD | 57.9x | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 51.8 % |
